Predictive value of NLR, Fib4, and APRI in the occurrence of liver failure after hepatectomy in patients with hepatocellular carcinoma

Table 4 Comparison of clinical data between the validation cohort with liver failure and the cohort without liver failure, n (%) or mean ± SD

Index		Liver failure group (n = 21)	No liver failure group (n = 45)	χ2	P value
Gender	Male	11 (52.38)	27 (60.00)	0.891	0.345
	Female	10 (47.62)	18 (40.00)
Age (yr)		52.84 ± 2.54	52.76 ± 2.19	0.131	0.896
BMI (kg/m2)		21.33 ± 2.08	21.29 ± 2.25	0.069	0.945
Smoking history	No	12 (57.14)	20 (44.44)	0.015	0.904
	Yes	9 (42.86)	25 (55.56)
Drinking history	No	11 (52.38)	24 (53.33)	0.187	0.665
	Yes	10 (47.62)	21 (46.67)
Hepatitis B	No	11 (52.38)	27 (60.00)	0.891	0.345
	Yes	10 (47.62)	18 (40.00)
Tumor diameter	< 5 cm	15 (71.43)	21 (46.67)	1.939	0.164
	≥ 5 cm	6 (28.57)	24 (53.33)
Liver cirrhosis	No	13 (61.90)	30 (66.67)	4.785	0.029
	Yes	8 (38.10)	15 (33.33)
Number of tumors	< 2	11 (52.38)	24 (53.33)	0.187	0.665
	≥ 2	10 (47.62)	21 (46.67)
Child-Pugh classification	Grade A	3 (14.29)	18 (40.00)	4.381	0.112
	Grade B	9 (42.86)	14 (31.11)
	Grade C	9 (42.86)	13 (28.89)
Surgical site	Left half liver	5 (23.81)	17 (37.78)	25.414	0.000
	Right half liver	6 (28.57)	28 (62.22)
	Bilateral hemiliver	10 (47.62)	0 (0.00)
AFP	< 400 μg/L	15 (71.43)	21 (46.67)	1.939	0.164
	≥ 400 μg/L	6 (28.57)	24 (53.33)
NLR		6.97 ± 3.41	3.33 ± 0.09	7.220	0.000
Fib4		10.54 ± 4.12	6.41 ± 1.99	5.516	0.000
APRI		0.75 ± 0.21	0.43 ± 0.15	7.080	0.000

AFP: Alpha-fetoprotein; BMI: Body mass index; NLR: Neutrophil-lymphocyte ratio; Fib4: Fibrosis index based on four factors; APRI: Aspartate aminotransferase-to-platelet ratio index.